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Background: The vaccine industry is one of the most important health-related industries. It can be affected by
accession to the World Trade Organization (WTO) because of probable dramatic changes in the business
environment. Iran has already initiated accession negotiations.
Purpose of the study: In this paper, we investigate the position of, challenges to, and opportunities for vaccine
manufacturing in Iran with regard to accession to the WTO.
Methods: This is a qualitative and cross sectional study. To collect information, we designed a questionnaire and
interviewed some of the vaccine industry’s key opinion leaders in Iran. Before the interviews were conducted,
the questionnaires were sent to these individuals by email.
Results: According to the interviewees, the country’s main challenges with regard to accession to the WTO are
the lack of firm internal intellectual property (IP) rules, not being recognized as pre-qualified by the World Health
Organization (WHO), the use of old equipment, and a lack of cooperation with global vaccine companies.
Major conclusions: Iran’s local vaccine industry, with a long history and international reputation that could be
used as an advantage, is faced with several challenges, such as problems with keeping up with Current Good
Manufacturing Practice (cGMP), a lack of adequate and meaningful investment in research and development (R&D),
and limitations on private sector participation in the production of vaccines.
Gradual privatization of the industry, improved international relations, utilization of the R&D power of small hi-tech
companies, consistent education of human resources, and modernization of infrastructures and equipment are
among the suggested solutions.
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Globalization could be defined as the process of making
nationalization irrelevant in markets, laws, and politics
in the production of common goods, based on compara-
tive advantages [1].
Today, most countries have joined the World Trade
Organization (WTO) and some are observer members
waiting to start negotiations in the accession process [2].
Iran (the Islamic Republic of Iran) was accepted into
this organization in 2005 as an observer member. The* Correspondence: Kebriaee@tums.ac.ir
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distribution, and reproduction in any mediumIranian trade regime report was sent to the WTO in 2009,
and currently, the first level of negotiation is on the table.
Accession to the WTO most probably affects many
aspects of various industries; being familiar with these
effects can provide organizations opportunities to deal
with the potential challenges that lie ahead. Among
these industries, those related to public health, such as
the pharmaceutical and vaccine industries, are extremely
vulnerable and sensitive: “vulnerable” because they are
faced with competition from big international companies
inside and outside of the country, and “sensitive”
because these industries are related to one of the most
important aspects of people's life—their health—especially
in developing countries where accessibility to medicines and
vaccines has been improved by domestic manufacturing.ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Razi Serum and Vaccine Research Institute started
manufacturing veterinary vaccines in 1929, and soon
after, added human products to its agenda [3]. The Insti-
tute Pasteur of Iran is the second vaccine manufacturer
in Iran. It started in 1920 with the cooperation of the
Institute Pasteur of France [4].
With regard to human vaccines, Razi produces mea-
sles, polio, MMR, MR, trivalent vaccines, and divalent
vaccines. The Institute Pasteur produces BCG and
Hepatitis B vaccines.
These two vaccine producers experienced glorious
periods in the past. To ensure continued success, the
Iran vaccine industry needs to determine its weaknesses
and strengths as well as the obstacles and opportunities
that lie ahead with regard to WTO accession.
The aim of this study is to assess the probable impacts
of WTO accession on the vaccine industry in Iran.
Method
This is a qualitative cross sectional study to investigate the
current situation as well as the upcoming issues affecting
the vaccine industry in Iran. To collect data and informa-
tion, we interviewed some of the key opinion leaders in the
Iranian vaccine industry. This group of experts was com-
prised of representatives from both local vaccine manufac-
turers and the Ministry of Health. We designed an open
questionnaire, including 13 questions that were asked orally.
The questions were classified in 6 groups in terms of
the subject:
1- The need for vaccines in Iran in terms of the
current health conditions.
2- The vaccine supply in Iran.
3- The effect of international relationships on the
vaccine supply in Iran.
4- The vaccine production capacity in Iran in case
of crises.
5- The introduction of model countries to the Iranian
vaccine industry.
6- The importance of international cooperation in the
vaccine industry and Iran’s current status.
7- The current technology level in Iran’s vaccine
industry.
8- The current human resources situation in Iran’s
vaccine industry.
9- The current situation regarding R&D investment in
Iran’s vaccine industry.
10- Public and private sector partnerships in the
Iranian vaccine industry.
11- The probable challenges in WTO accession.
12- Iran’s ability to compete in the international
vaccine market.
13- Suggested solutions.In the first question, our aim was to collect informa-
tion about Iran’s domestic vaccine market and immuni-
zation trends in Iran.
In questions 2, 3, and 4, we asked the experts about
the capabilities of Iran’s production of necessary vaccines
in routine situations and in the event of a crisis.
In questions 5 and 6, we asked about the country’s
vaccine manufacturers’ international cooperation and
their visions and patterns for the future.
In questions 7, 8, and 9, we were searching for an
evaluation of three important factors—the level of tech-
nology, human resources, and R&D—in the Iranian
vaccine industry.
In question 10, we asked about possession and owner-
ship issues in the vaccine industry in Iran.
Questions 11, 12, and 13 reflect an international mar-
ket perspective and Iran’s ability to penetrate these mar-
kets after WTO accession. We wanted to know about
the challenges ahead and the experts’ suggested solutions
for overcoming them.
The questionnaires were sent to the interviewees
before the interviews.
Among the 16 respondents selected, 11 of the key
opinion leaders opted to answer the questions orally.
Some of these interviewees only answered some of the
questions. Two interviewees preferred to communicate
through email, and one of these answered only half of
the questions.
Results
The need for vaccines in Iran in terms of the current
health conditions
The interviewees believed that, regarding routine and
traditional vaccines, the immunization coverage in terms
of the health conditions (polio has been eradicated, and
some diseases, like measles, are expected to be eradi-
cated soon) is adequate. However, the young population
and the geographic position of Iran, which neighbors
poor countries like Iraq and Afghanistan in terms of
health conditions, and illegal immigrants coming from
these countries makes Iran vulnerable to the transmis-
sion of diseases coming from outside of its borders.
Additionally, the large number of foreign trips embarked
upon by Iranian citizens, like the Hajj pilgrimage,
and communication with people from poor-health-
conditioned countries, such as some African countries,
are threats to the current domestic situation.
Two of the interviewees believed that the need for vac-
cines is independent of the prevailing health conditions
and is almost constant and contingent upon the popula-
tion. Another interviewee highlighted the increasing
need for vaccines in Iran because of the young popula-
tion, illegal immigration from neighboring countries
(without powerful governments and health systems), and
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health care in some parts of Iran.
The vaccine supply in Iran, the effect of international
relationships, and the vaccine production capacity
in Iran in case of crises
Only 9 out of 11 interviewees answered the first ques-
tion about the vaccine supply in Iran. All of them
believed that most of Iran’s vaccine supply is supported
by two local manufacturers and, each year, shortages are
compensated by import. We were not able to access
accurate information about the vaccine market value
and market share of Iranian manufacturers, but an esti-
mation by the drug office of the Food and Drug
Organization (FDO) from the Health Deputy’s orders for
vaccines shows that sales have been 250 to 400 billion
Rials annually for the past five years, depending on the
year’s requirements. No separate data was available about
the value and volume of domestic and imported vaccines.
Ten interviewees answered the second question regard-
ing the effects of international relationships on the vac-
cine supply. Two respondents thought that international
relationships were important and one thought that inter-
national relationships would greatly affect the vaccine
supply. The other respondents went into detail regarding
their opinions: they felt that the main effects of inter-
national relationships are on the transfer of technology
and access to modern equipment, and that the vaccine
supply is not greatly influenced by political issues.
Ten out of 11 interviewees answered the question
about Iranian manufacturers’ capacity to supply the
needed vaccines in the event of crises. Seven respon-
dents said that, with concentration on the vaccine indus-
try, Iran would be able to cover its domestic needs in
crises and extraordinary situations.
The introduction of model countries and the importance
of international cooperation in the vaccine industry
Eleven persons expressed their thoughts on model coun-
tries for the Iranian vaccine industry. They listed various
countries among their answers: Turkey, Pakistan, Jordan,
Egypt, the USA, Canada, India, the European countries,
Japan, South Korea, Indonesia, Cuba, and Thailand.
Out of these countries, India (seven persons), Indonesia
(six persons), and Cuba (four persons) were the most
mentioned. Four out of the 11 key opinion leaders
believed that developed countries like the USA, Japan,
and Canada should be used as models, while the
others emphasized the significance of economic sim-
ilarity between Iran and the model countries. They
selected their models from developing countries with
WHO prequalification.
Regarding the importance of international cooperation
between vaccine companies and the current situation inIran, 9 out of the 10 persons who answered this ques-
tion pointed to the importance of this relationship with
certainty. Seven out of 11 interviewees found Iran’s
current situation undesirable and two of them did
not respond.
The current situation in Iran’s vaccine industry regarding
technology, human resources, and R&D
Regarding the level of technology, 10 out of 11 respon-
dents mentioned difficulties in accessing new equipment.
Three of them found that the position of the Institute
Pasteur was superior to the Razi Institute because it has
newer facilities. Regarding the level of technology in vac-
cine manufacturing, two out of seven respondents said
that Iranian methods of vaccine production are current
and are based on international protocols, and the only
problem is accessing new equipment; however, four
of these seven felt that the vaccine technology level is
undesirable and that Iran is not in a good global pos-
ition. Nine respondents believed that Iran has achieved
significant improvements in biotechnology in recent
years but that these achievements have not yet been fully
exploited. All of those with positive outlooks regarding
the level of technology were representatives from Iranian
vaccine manufacturers.
Four out of 10 interviewees who answered the ques-
tion regarding the human resource situation called it
satisfactory and the others mentioned some weaknesses,
like the shortage of well-educated persons and experts in
the industry, the lack of industry skills in university
graduates, problems in consistent education within the
industry, and the lack of cooperation between Iranian
and foreign vaccine makers in the field of human
resources enhancement.
Nine persons responded to the question about R&D.
All of them called the investment of local Iranian
manufacturers in R&D negligible in comparison with
international norms. Five persons believed that the Insti-
tute Pasteur’s investment in R&D is superior to that
of the Razi Institute. Low levels of investment, non-
applicable and non-targeted research, and problems in
R&D management were the main issues presented by
the interviewees.
Public and private sector partnerships
All 11 persons who responded to this question stated
that the private sector does not have a role in vaccine
production in Iran. Three pointed out the tendency
of the private sector to engage in vaccine production.
The extent of private sector participation in vaccine
development and production in Iran is very small and
limited to a few companies that import vaccines ordered
by the government. One interviewee believed that the
only route of entry into this market is focusing on
Table 1 Immunization schedule of expanded program of
immunization program in Iran, 2010
Age of vaccination Type of vaccine
At birth BCG, OPV, Hep B
2 month OPV, DTwP, HepB
4 month OPV, DTwP
6 month OPV, DTwP, Hep B
12 month MMR
18 month OPV, DTwP, MMR
6 years OPV, DTwP
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believed that most of the problems in Iran’s vaccine
industry are related to its public structure.
Iran’s ability to compete in the international market,
the probable challenges to WTO accession, and
suggested solutions
For the question about Iran’s ability to compete in the
international vaccine market, two experts responded
positively and three believed that it is not possible for
Iran to compete. The others believed there is a
provisional possibility. Four interviewees stated that this
ability depends on obtaining WHO prequalification and
one person stated that this ability depends on using
current capacities and expanding upon them.
Ten out of 11 interviewees commented on the prob-
able challenges to the vaccine industry during WTO ac-
cession. One of them believed that joining the WTO
would be detrimental to the vaccine industry in Iran, but
he did not provide any support for his opinion. Another
respondent believed that IP issues are the main chal-
lenges. Other challenges mentioned included outdated
equipment and political challenges, like sanctions and
lack of international cooperation. Not being prequalified
(one person) and weaknesses in state-run industries
(one person) were the other ideas. Two believed there
are no challenges, as the country is able to overcome
any obstacles by using WTO flexibilities.
These key opinion leaders believed in the effectiveness
of the following solutions: privatization of the industry
(four persons), consistent education for employees (three
persons), allowing private sector involvement along with
the government in production (two persons), using the
capacity of small science-based companies in R&D and
related areas (two persons), the improvement of inter-
national cooperation in the vaccine industry (one per-
son), the resolution of political challenges (one person),
and determination and implementation of IP rights in
Iran with the help of foreign consultants (one person).
Discussion
Need for vaccines in Iran in terms of the current
health conditions
Vaccines needed for immunization programs in Iran
(EPI) include BCG, DTP, HepB, polio, and MCV (see
Table 1). The influenza, rabies and HPV vaccines (all
imported from other countries) are available on the mar-
ket but not in the EPI and there is still a clear lack of
availability of Haemophilus influenza type B (Hib) and
rotavirus vaccines in EPI. According to an internal study,
the prevalence of Hib carriers is 7.6%, similar to other
developing countries, yet this vaccine is still not part of
the program [5]. The government intends to include
these two vaccines in the program; this is dependentboth on adding them to the Iranian drug list and the
ability of vaccine producers to produce them, which has
not been the case so far. It should be emphasized that
Iran has already adopted a National Drug List (NDL),
which is selected by the Iran Drug Selecting Committee
(IDSC). All drug supply management process, including
registration, procurement, inspection, quality control,
and post marketing control, can be handled by the IDSC
for a drug that is accepted for inclusion on the NDL [6].
The vaccine supply in Iran, the effect of international
relationships, and the vaccine production capacity in Iran
in case of crises
It seems there is no clear vision in Iran regarding the
vaccine supply in the future. The world’s approach
toward combo vaccines and changes in the type of
vaccines, such as the expanded use of inactivated polio
vaccine (IPV) instead of oral polio vaccine (OPV) and
the probable eradication of some diseases within the
country in the coming years, could significantly affect
Iran's vaccine industry.
With the advent of new diseases and phenomena like
bioterrorism, the capacity for vaccine production has
become increasingly important. Some developed countries,
such as the United Kingdom [7] and the United States
[8] have invested in this sector to assure their ability to
control such threats. The Iranian vaccine industry has
illustrated its abilities to supply domestic need in crises;
the main example of this is its performance during the
imposed war with Iraq. As most key opinion leaders
stated, they are not concerned about crises, however, the
country must continually increase its capacity.
The introduction of model countries and the importance
of international cooperation in the vaccine industry
There was general agreement among those interviewed
regarding international cooperation for growth in this
industry. Today, the importance of collaboration by vac-
cine makers in developing countries has become clear.
The LG Company in Korea, which has obtained WHO
prequalification, is establishing strategic cooperation in
the field of R&D with large vaccine companies [9].
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such cooperation by the Institute Pasteur for production
of pentavalent vaccine and other biotechnology products
with countries such as Cuba, India, Malaysia, and France
has already been enacted [10], although most of the
interviewees found these partnerships to be very limited,
especially in the case of the Razi Institute.
The current situation of Iran’s vaccine industry regarding
technology, human resources, and R&D
According to the interviewees, there are lesser problems
in access to technology for traditional and well-
established vaccines; however, because of the current
and upcoming changes in the methods of producing
these vaccines, Iran’s vaccine industry needs to be
updated by acquiring new technologies for surviving
international competition. In the field of newer vaccines,
access to equipment and devices, especially access to
technology, is influenced dramatically by political issues.
It seems that despite highly educated professionals in
this industry, the human resources situation in Iran is
far from ideal because of the lack of regular targeted
training and the need for updated knowledge and infor-
mation, which could be because of governmental struc-
ture and political problems and challenges.
The best source for R&D work on the diseases of
developing countries is the countries where the diseases
are endemic. The Commission on Health Research for
Development in 1990 showed that only 10% of invest-
ment in health research is allocated to 90% of the dis-
eases and health problems of the world. This is called
the 10/90 gap. Children in developing countries do not
benefit from advances in the field of vaccines in richer
countries [11]. Iran could recognize the vaccine market
in developing and less developed countries and manage
research and development investments toward their
needs to be able to use these opportunities in the future.
By following the current approach in the management of
R&D in Iran, the vaccine industry will not be able to
participate in global markets or even cover domestic
needs. According to an internal report by the Razi Insti-
tute [12], the rate of capital invested by the Razi Institute
in R&D in the annual budget is only 2%; in light of
the large areas of activity in this institute in the field of
vaccines and serums (human and animal), this seems to
be a very limited amount.
Public and private sector partnerships
The Ministry of Health is responsible for supplying the
needed vaccines and planning the vaccination programs.
In Iran, the government is involved in both produc-
ing and supplying vaccines. The Institute Pasteur is
under supervision of the Ministry of Health and the Razi
Institute operates under the Ministry of Agriculture.However, because of being regarded as a strategic indus-
try for Iran in the area of national security, the pos-
sible privatization of these two vaccine makers is not
imminent. As previously stated, it seems that the pres-
ence of the private sector along with the public sector
would help the vaccine industry to overcome many pro-
blems, such as efficiently maintaining and strengthening
human resources, managing and optimizing targeted
areas of R&D capacities, and the provision on opportun-
ities to establish a presence in international markets.
Several factors impede the private sector from becoming
involved in vaccine production. The only purchaser
for the EPI vaccine is the government and because both
vaccine manufacturers belong to the government, there
is not an opportunity for the private sector to become
involved in such a market. The government prefers to
have complete authority in vaccine production and sup-
ply so that it can assure a consistent supply regardless of
gain or loss (which is the main incentive for the private
sector) at different times and in different situations.
Iran’s ability to compete in international markets,
the probable challenges to WTO accession,
and suggested solutions
Most expert interviewees feel that the first step in
moving toward international market status is obtaining
WHO prequalification for the country’s vaccines. Today,
many countries are faced with several problems in sup-
plying essential vaccines. Concerns in this regard
increased after the implementation of IP rules and
discussions related to world trade [13]. But some
vaccine-related agencies, such as the United Nations
Children's Fund (UNICEF) and the Pan American
Health Organization (PAHO), and government–private
cooperatives, like the Global Alliance for Vaccines and
Immunization (the GAVI Alliance), are working to help
these countries. GAVI, for example, aims to increase the
economic attractiveness of the market by stimulating
vaccine demand in developing countries, as well as
strengthening infrastructure and ensuring their ability to
procure such products [14]. UNICEF also purchases
about 55% of the world’s vaccines [15]. The World
Health Organization grants prequalification to ensure
that UN agencies buy quality, safe, and efficacious
vaccines. According to internal news, Iran’s National
Regulatory Authority (NRA) recently gained WHO pre-
qualification, but many problems concerning cGMP
compliance still require resolution. Unfortunately, due to
lack of sufficient investment, it is not possible to up-
grade the facilities and equipment at the Razi Institute
to comply with the principles of cGMP. However, most
interviewees believed that it will be easier to obtain these
standards by the Institute Pasteur’s new facility (where
the Hep B vaccine is manufactured).
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very important because it is directly related to the coun-
try’s public health. Therefore, it is necessary to under-
stand the WTO rules affecting this industry. Three
agreements— “Trade Related Aspects of Intellectual
Property Rights (TRIPs),” “Subsidies and Compensatory
Measures,” and “Government Procurement Agreement
(GPA)”—could be associated with this industry and must
be carefully considered. Here, we review one of the most
important agreements: TRIPS.TRIPs: Intellectual prop-
erty right is considered as an asset by companies which
could be seen as patents, distinctive signs, copyright,
industrial designs and trade secrets [16]. In pharmaceu-
ticals, patent rights cause a monopoly for patent holders
by preventing others from using a particular invention
for a specified period of time [17]. Nevertheless, to
resolve the concerns of developing countries [18], the
TRIPs agreement offers some flexibility for govern-
ments in providing their social goals. Transition periods,
compulsory licenses, and parallel importation are from
such flexibilities [19]. But in terms of being influenced
by TRIPs, there are some differences between vaccines
and other pharmaceutical products. The most important
difference is the complexity of the processes used to
manufacture biological products like vaccines. There are
considerable scientific techniques and secrets (know-
how) in the manufacturing processes of such products
that companies prefer to maintain in-house as trade
secrets and which will not be disclosed; therefore, com-
pulsory licenses would not be all that useful [20].
Another issue is that it has become usual to patent one
or more of the vaccine components, such as adjutants
[21]. In a study conducted in 2005, the World Health
Organization showed that most suppliers of vaccines in
developing countries have not considered that IP plays
an important role in vaccine R&D [22]. Iranian drug
policy makers should also ensure efficacy, quality, and
safety measures by full adherence to Iranian national
drug policy rules [23]. These issues should be paid
adequate attention before proceeding to WTO accession.
Conclusions
Both strengths and weaknesses were found in the Iran-
ian vaccine industry, although the weaknesses outweigh
the strong points. Considering the fact that it is a large
market in relation to its young population and large area
as well as its specific geographical location (associated
with the war-torn countries without strong health
systems and appropriate levels of health), Iran is experi-
encing an ever-increasing need to supply vaccines; the
increasing need and market could be an opportunity for
this industry, even on a domestic level. The long history
and reputation of Iran’s local vaccine industry could be
considered advantages. However, this industry is facedwith some weaknesses, such as non-compliance with
cGMP, a lack of adequate and meaningful investment in
R&D, a lack of mutual reliance of the government on
the private sector in vaccine production, and the pro-
blems and political challenges that have hindered the
development of this industry. According to most of the
key opinion leaders, the most significant problem in
Iran’s vaccine industry has roots in its government
ownership, which cannot be quickly solved.
Some useful solutions for improving the position of
this industry in international competition include: a)
privatization of current vaccine manufacturers (in the
long-term) and relying on private vaccine producers to
come into the field, b) improving international relations
and cooperation with the large vaccine manufacturers in
the world, c) utilizing small knowledge-oriented com-
panies with the aim of fueling R&D, d) consistent educa-
tion for employees, e) investment in order to modernize
the old infrastructure of the Razi Institute regarding
compliance with the principles of cGMP to achieve
international quality standards to facilitate WHO pre-
qualification. For the implementation of these strategies
and to minimize the negative effects of implementing
WTO agreements like GPA, TRIPs, and subsidies and
compensatory measures, the role of negotiation teams in
the accession process is extremely crucial. These teams
should be familiar with the status of the vaccine indus-
try. Achieving agreement among the industry’s key opin-
ion leaders about the future of this industry in the
process of WTO accession can facilitate the negotia-
tions. It is obvious, then, that recruiting professional
experts in this field is necessary for this purpose.
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